{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:27:54Z","timestamp":1762867674353,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.endien.2021.10.008","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T13:06:57Z","timestamp":1635944817000},"page":"439-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term effect of combined therapy with somatostatin analogs and dopamine agonists as a primary treatment in a non-functioning invasive pituitary macroadenoma"],"prefix":"10.1016","volume":"68","author":[{"given":"Pedro","family":"Iglesias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2021.10.008_bib0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endien.2021.10.008_bib0070","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1055\/s-0043-115645","article-title":"Prevalence, clinical features, and natural history of incidental clinically non-functioning pituitary adenomas","volume":"49","author":"Iglesias","year":"2017","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.endien.2021.10.008_bib0075","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2002-36708","article-title":"Gonadotropinomas","volume":"20","author":"Chaidarun","year":"2002","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.endien.2021.10.008_bib0080","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11102-018-0868-4","article-title":"Management of nonfunctioning pituitary tumors: radiotherapy","volume":"21","author":"Minniti","year":"2018","journal-title":"Pituitary"},{"issue":"56","key":"10.1016\/j.endien.2021.10.008_bib0085","article-title":"The expression profile of dopamine D2 receptor MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy","volume":"33","author":"Wang","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.endien.2021.10.008_bib0090","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1210\/jcem-71-3-718","article-title":"Bromocriptine increasingly suppresses the in vitro gonadotropin and alpha-subunit release from pituitary adenomas during long term culture","volume":"71","author":"Kwekkeboom","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2021.10.008_bib0095","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF03343756","article-title":"Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma","volume":"23","author":"Giusti","year":"2000","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.endien.2021.10.008_bib0100","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.mce.2007.12.008","article-title":"Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas","volume":"286","author":"Saveanu","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.endien.2021.10.008_bib0105","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fendo.2018.00469","article-title":"Dopamine agonists for pituitary adenomas","volume":"9","author":"Cooper","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.endien.2021.10.008_bib0110","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1210\/jc.2011-3163","article-title":"Expression of Ki-67, PTTG1 FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study","volume":"97","author":"Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2021.10.008_bib0115","doi-asserted-by":"crossref","first-page":"E533","DOI":"10.1227\/NEU.0000000000001389","article-title":"Congress of neurological surgeons systematic review and evidence-based guideline on primary management of patients with nonfunctioning pituitary adenomas","volume":"79","author":"Lucas","year":"2016","journal-title":"Neurosurgery"},{"key":"10.1016\/j.endien.2021.10.008_bib0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2265.2001.01172.x","article-title":"In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas","volume":"54","author":"Andersen","year":"2001","journal-title":"Clin Endocrinol (Oxf)."}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018021000901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018021000901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:15:17Z","timestamp":1762866917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018021000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2530018021000901"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2021.10.008","relation":{},"ISSN":["2530-0180"],"issn-type":[{"type":"print","value":"2530-0180"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effect of combined therapy with somatostatin analogs and dopamine agonists as a primary treatment in a non-functioning invasive pituitary macroadenoma","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2021.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}